A Review of the Diagnosis and Treatment of Ochratoxin A Inhalational Exposure Associated with Human Illness and Kidney Disease including Focal Segmental Glomerulosclerosis | Zendy

Janette Hope | Zendy; Bradley E. Hope | Zendy

Open Access

A Review of the Diagnosis and Treatment of Ochratoxin A Inhalational Exposure Associated with Human Illness and Kidney Disease including Focal Segmental Glomerulosclerosis

Author(s) -

Janette Hope,

Bradley E. Hope

Publication year - 2011

Publication title -

journal of environmental and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.869

H-Index - 35

eISSN - 1687-9813

pISSN - 1687-9805

DOI - 10.1155/2012/835059

Subject(s) - ochratoxin a , focal segmental glomerulosclerosis , medicine , kidney disease , disease , kidney , ochratoxin , ingestion , physiology , intensive care medicine , glomerulonephritis , mycotoxin , microbiology and biotechnology , biology

Ochratoxin A (OTA) exposure via ingestion and inhalation has been described in the literature to cause kidney disease in both animals and humans. This paper reviews Ochratoxin A and its relationship to human health and kidney disease with a focus on a possible association with focal segmental glomerulosclerosis (FSGS) in humans. Prevention and treatment strategies for OTA-induced illness are also discussed, including cholestyramine, a bile-acid-binding resin used as a sequestrant to reduce the enterohepatic recirculation of OTA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research